

**Analogs of Galanthamine and Lycoramine as Modulators of Nicotinic Receptors****Abstract of the Disclosure**

A method for treating the effects of low LDL-cholesterol values in the brain on cognitive performance or other central nervous system functions by modulating nicotinic receptors by administering an effective amount of a nicotinic allosteric potentiator, an acetylcholinesterase inhibitor, nicotine, a nicotinic agonist or a mixture thereof to a patient in need of such modulation.

20170828.031402